Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: The example of ketolides

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Opatowski, Lulla ^a,b   Temime, Laura ^c   Varon, Emmanuelle ^d   Leclerc, Roland ^e   Drugeon, Henri ^f   Boëlle, Pierre Yves ^b,g,h   Guillemot, Didier ^a,b,i,j  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c Bioinformatique et Chimie Moléculaire   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f Laboratoire de Virologie   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j RAYMOND POINCARÉ HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; KETOLIDE; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; BACTERIAL VACCINE; PENICILLIN DERIVATIVE; VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CHILD; COMMUNITY; CONTROLLED STUDY; CROSS RESISTANCE; DIFFUSION; DRUG EXPOSURE; DRUG USE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY TRACT INFECTION; SIMULATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; DEMOGRAPHY; DISEASE TRANSMISSION; DRUG EFFECT; FRANCE; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MICROBIAL; FRANCE; HUMANS; INFANT; INFANT, NEWBORN; KETOLIDES; PENICILLINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 47749141527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002089     Document Type: Article

References (55)

1. Davis SR (2000) The state of antibiotic resistance surveillance: an overview of existing activities and new strategies. Mil Med 165: 35-39.
2. Tomasz; A (1997) Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 24: S85-88.
3. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-S129.
4. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, et al. (2000) Mortality from invasive pneumucoccal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 90: 223-229.
5. Obaro SK, Adegbola RA, Banya WA, Greenwood BM (1996) Carriage of pneumococci after pneumococcal vaccination. Lancet 348: 271-272.
6. European Antimicrobial Resistance Surveillance System (EARSS) (2006) Annual Report 2005. Available: http://www.rivm.rd/earss/result/ Monitoring_reports.
7. Cassell GH, Mekalanos J (2001) Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 285: 601-605.
8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
9. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, et al. (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455-1463.
10. Pichichero ME, Casey JR (2007) Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298: 1772-1778.
11. Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, et al. (2007) Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 26: 485-490.
12. Institut National de la Statistique et des Etudes Economiques (INSEE) (2007) Indices et series statistiques. Demographie. Available: http://www.insee.fr/fr/home/home_page.asp. Accessed January 2005.
13. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, et al. (2004) Nasopharyngeal carriage of Strepiococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 38: 632-639.
14. Hendley JO, Sande MA, Stewart PM, Gwaltney JMJ (1975) Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis 132: 55-61.
15. Ekdahl K, Ahlinder I, Hansson HB, Melander E, Molstad S, et al. (1997) Duration of nasopharyngeal carriage of penicillin-resistant Streplococcus pneumoniea: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis 25: 1113-1117.
16. Melegaro A, Gay NJ, Medley GF (2004) Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect 132: 433-441.
17. Cauchemez S, Temime L, Valleron AJ, Varon E, Thomas G, et al. (2006) S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools. BMC Infect Dis 6: 14.
18. Hogberg L, Geli P, Ringberg H, Melander E, Lipsitch M, et al. (2007) Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J Clin Microbiol 45: 948-952.
19. (2002) Advice of the French Superior Council on Public Health (section on transmissible diseases) relative to vaccination by heptavalent pneumococcal conjugate vaccine (Prevenar). Meeting of March 8, 2002. Arch Pediatr 9: 862-864.
20. Centers for Disease Control and Prevention (CDC) (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices for use of PCV7 in the USA. MMWR 49: 1-38.
21. Centers for Disease Control and Prevention (CDC) (2004) Updated recommendations for use of pneumococcal conjugate vaccine. MMWR 53: 177-178.
22. Institut de Veille Sanitaire (InVS) (2006) Calendrier vaccinal 2006. Bulletin Epidémiologique Hebdomadaire 29-30: 212.
23. Temime L, Guillemot D, Boelle PY (2004) Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance. Antimicrob Agents Chemother 48: 2206-2213.
24. Temime L, Guillemot D, Boche PY (2006) Pneumococcal resistance in the postvaccine era. Pediatr Infect Dis J 25: 382-383.
25. French National Health Insurance. French Surveillance of Antimicrobial Consumption Program, CNAM-TS and CANAM. Available: http://www.ameli.fr/.
26. Hakenbeck R, Grebe T, Zahner D, Stock JB (1999) beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol 33: 673-678.
27. Wierzbowski AK, Boyd D, Mulvey M, Hoban DJ, Zhanel GG (2005) Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. Antimicrob Agents Chemother 49: 4635-4640.
28. Leclercq R (2002) Will resistance to ketolides develop in Streptococcus pneumoniae? J Infect 44: 11-16.
29. Goldstein F, Vidal B, Kitzis MD (2005) Telithromycin-resistant Streptococcus pneumoniae. Emerg Infect Dis 11: 1489-1490.
30. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, et al. (2005) Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 11: 851-858.
31. Leclercq R (2001) Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 48: 9-23.
32. Sommet A, Sermet C, Boelle PY, Tafflet M, Bernède C, et al. (2004) No significant decrease in antibiotic use from 1992 to 2000, in the French community. J Antimicrob Chemother 54: 524-528.
33. Geslin P, Fremaux A, Sissia G, Spicq C, Zberrane S (1992-2000) Centre National de Référence des Pneumocoques. Rapports d'activité.
34. Varon E, Gutmann L (2003) Centre National de Référence des Pneumocoques. Rapport d'activité 2003: Epidémiologie 2002.
35. Varon E, Gutmann L (2005) Centre National de Référence des Pneumocoques. Rapport d'activité 2005: Epidémiologie 2002.
36. Decousser JW, Ovetchkine P, Collignon A, Chaplain C, Estrangin E, et al. (2004) Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ile de France area. Eur J Clin Microbiol Infect Dis 23: 27-33.
37. Farrell DJ, File TM, Jenkins SG (2007) Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 45: 290-293.
38. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV Model, as an example. International Statistical Review 62: 229-243.
39. Lipsitch M (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5: 336-345.
40. Lipsitch M (2001) Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 32: 1044-1054.
41. Temime L, Boelle PY, Courvalin P, Guillemot D (2003) Bacterial resistance to penicillin G by decreased affinity of penicillin-binding proteins: a mathematical model. Emerg Infect Dis 9: 411-417.
42. Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, et al. (2005) Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365: 855-863.
43. Malley R, Srivastava A, Lipsitch M, Thompson CM, Watkins C, et al. (2006) Antibody-independent, interleuidn-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun 74: 2187-2195.
44. Andersson DI (2006) The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9: 461-465.
45. Trzcinski K, Thompson CM, Gilbey AM, Dowson CG, Lipsitch M (2006) Incremental increase in fitness cost with increased beta-lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. J Infect Dis 193: 1296-1303.
46. Rozen DE, McGee L, Levin BR, Klugman KP (2007) Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 51: 412-416.
47. U.S. Food and Drug Administration (FDA) (2007) Updated label for Ketek (telithromycin). Available: http://www.fda.gov/cder/drug/infopage/ telithromycin/. Accessed May 2007.
48. Ross DB (2007) The FDA and the case of Ketek. N Engl J Med 356: 1601-1604.
49. Soreth J, Cox E, Kweder S, Jenkins J, Galson S (2007) Ketek-the FDA perspective. N Engl J Med 356: 1675-1676.
50. Desenclos JG, Guillemot D (2004) Consequences of bacterial resistance to antimicrobial agents. Emerg Infect Dis 10: 759-760.
51. Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, et al. (2001) Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 33: 797-805.
52. McGowan JE Jr (2001) Economic impact of antimicrobial resistance. Emerg Infect Dis 7: 286-292.
53. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, et al. (2006) Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657-668.
54. Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG (2004) Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 48: 605-607.
55. Wang YG, Lipsitch M (2006) Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. Proc Natl Acad Sci U S A 103: 9655-9660.